India overdependent on China for medicines – study

pharmaIndia may have emerged as a key supplier of generic and affordable medicine for the world market, but it has an “overwhelming dependence” on China for the raw material required to produce these drugs, industry association Assocham said.

Indian companies depend on China to supply them with the main raw material in drug making — known as Active Pharmaceutical Ingredient (API). The dependence is to the extent of over 65 per cent, an ASSOCHAM-RNCOS joint paper said.

Though the government has taken steps like withdrawal of exemption in customs duties , imports worth Rs 13,853 crore in 2015-16 or 65.29 per cent of the total imports of Rs 21,216 crore are not sustainable, the association said.

“This is all the more disconcerting in the face of louder narrative against reducing trade gap with China which is well over USD 51 billion,” it said.

The API is the organ by which active pharmaceutical ingredients are manufactured from raw materials through both chemical and physical means.

Rapid growth in new medical technologies is spurring the demand for APIs worldwide today with the increased import of raw pharma ingredients from the emerging markets.

“India’s rising dependence on imports from China for many APIs that go into the making of a number of essential drugs has been cited as an area of concern for the policy makers”.

“Over-dependence on China for APIs is likely to affect the bulk drug manufacturing sector, and subsequently have an impact on our population in plausible scenarios of drug shortages brought down by interrupted imports from single source country”, ASSOCHAM Secretary General Mr D S Rawat said, adding over-dependence on such a crucial raw material on a single country is also not advisable from India’s overall strategic interests as well.

One of the main reasons for huge API imports from China is low cost of its manufacture and subsidy in China while India levies negligible import fee . “The import fees should be increased in line with other counterparts”, the paper said.

The chamber said there is presence of multiple regulatory authorities for the industry. The API manufacturers have to approach different authorities for renewal of licences that become a tedious affair.

“Therefore a single committee of various government departments should be formed to regulate the industry through a single window and audit of plants”.
Besides, the Centre can focus on development of mega parks for APIs across the country. These parks should be provided with common facilities such as effluent treatment plants, testing, power plants, IPR management and designing. These facilities should be maintained by special purpose vehicles.

Several other countries like China provide incentives and subsidies for promoting the manufacture of essential pharmaceutical raw material. This significantly reduces their cost of production and ability to supply API to the world market at a huge discount to the global prices. This discourages new domestic investment in the sector.



TRUMP THREAT: TCS not worried, says we’re not the villains source: NasscomTata Consultancy Services, the largest Indian-owned outsourcing company, said it is able to manage with 75% less new visas this year as it has changed its business and recruitment models in recent years. It also said that outsourcing was key to protecting US jobs, and is not the villain as portrayed.The statement from Rajesh Gopinatha...
Cipla redraws Iran plans with new agreement, to invest Rs 121 cr Cipla said its wholly owned subsidiary of the Company in Netherlands will set up a 75% joint venture with Ahran Tejarat Company for manufacturing and marketing of pharmaceutical products in Iran.An earlier agreement executed by the Company with the Iranian firm has been terminated.The total investment will be euro 16.875 million, which comes to about...
Exports increase share of jobs in India – Study A new study by the Exim Bank has found that around 15% of the total jobs in India are related to India's exports sector, including both IT, BPO and material goods such as garments.The total number of jobs supported by aggregate Indian exports increased from about 34 million in 1999-00 to 62.6 million in 2012-13, with a growth rate of 3.4% per annum, ...
Despite Demonetization, India will beat China in GDP growth: Fitch Ratings Despite a moderation in India's GDP growth rate in the short term due to cash crunch, the Indian economy will still grow faster than that of China, global ratings agency Fitch said."We still expect India’s GDP growth to trend higher than China’s in the medium term," said the agency, whose primary job is to advice bond buyers on risks involved in buying d...
Bliss GVS Healthcare wins three-year contract worth Rs 760 cr from Kenya Bliss GVS Healthcare Ltd said it won a three year contract worth $111.40 mln (Rs 760 cr) from Aon Kenya Insurance Brokers Ltd for provision of medical health care services in Kenya. Bliss GVS Pharma Ltd is a pharmaceutical company based in Mumbai, India.Bliss GVS primarily develops, manufactures and markets products across various therapeuti...
Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta tablets of Boehringer Ingelheim Pharmaceuticals, Inc.An Abbreviated New Drug ...
Lupin launches injectable iron formulations in India Pharma major Lupin Limited said it launched Iron Isomaltoside injectable iron formulation under two brand names “Isofer” and “Jilazo” in India.Lupin acquired the exclusive rights to market, distribute and sell the injectable formulation from Denmark based Pharmacosmos A/S.The product is currently marketed in 33 countries, including 21 European Union coun...
Dr Reddy’s Labs launches osteoporosis drug in the US Dr Reddy's Laboratories Ltd said it launched raloxifene hydrochloride tablets --used to treat osteoporosis -- in the US market.Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, r...
Sun Pharma to get dengue vaccine technology from ICGEB Pharma major Sun Pharma said it tied up with research organization International Centre for Genetic Engineering and Biotechnology to develop vaccines for dengue.The vaccine is targeted against all the four serotypes of Dengue virus that cause disease in humans and is being developed to commercialize in Indian and international markets.A serotype is a...
Aarti Industries to return Rs 96 cr to shareholders via buyback Speciality Chemicals company Aarti Industries Ltd said it will buy back12 lakh equity shares at Rs 800 each, aggregating to Rs 96 cr.The company´s Board of Directors approved the equity shares -- representing up to 1.44% of the company's base."The public announcement setting out the process, timelines and other requisite detail will be released in du...
Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets Marksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules -- a synthetic equivalent of Vitamin D.Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol Capsules are therapeutically equivalent to the reference l...
Lupin licenses taste-masking technology from Monosol for paediatric tablets Pharma Major Lupin Ltd. said its US subsidiary, Lupin Pharmaceutical Inc., has agreed to license technology from Monosol Rx to develop multiple paediatric-focused products.Lupin would develop the pediatric products utilizing MonoSol Rx’s proprietary PharmFilm drug delivery technology.MonoSol Rx’s PharmFilm technology is a drug delivery platform tha...
Cadila to launch immunosuppressant drug in India Cadila Healthcare, a Ahmedabad headquartered pharmaceutical company owned by Zydus Group, said it has partnered with Switzerland-based global biopharmaceutical company Neovii to launch an drug to reduce the strength of the body's immune system in India.The drug named Grafalon is extensively used in solid organ transplants and stem cell transplant, said t...
Almebic Pharmaceuticals receives inspection report from USFDA Alembic Pharmaceuticals Ltd., said it received an Establishment Inspection Report from the United States Food and Drug Administration for the inspection carried out at their formulation facility at Panelav, Gujarat.The FDA has the authority to inspect any establishment in which food is manufactured, processed, packed, or held, in search of contamination....
Shilpa Medicare receives USFDA approval for generic bone marrow drug Shilpa Medicare Ltd said it received an approval from the United states Food & Drug Administration for Azacitidine injection.Azacitidine is used to treat myelodysplastic syndrome - a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells.The approval was received under ...